CS1P1 PET Studies of Neuroinflammation in Parkinson Disease

The Washington University

Status

Invitation-only

Conditions

Parkinson Disease

Treatments

Drug: [11C]-CS1P1

Study type

Observational

Funder types

Other

Identifiers

NCT06084533

202306067

Details and patient eligibility

About

Parkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking. Based on prior research, the investigators think that small amounts of inflammation in the brain may contribute to the mobility and thinking problems in people with PD. They are trying to measure inflammation in the brain in order to understand how this inflammation could be contributing to the symptoms of PD. This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called [11C]-CS1P1 to identify inflammation in the brain.The goal of this project is to quantify neuroinflammation with [11C]-CS1P1 PET and compare to motor and cognitive function in participants with various stages of severity of PD compared to controls.

Enrollment

80 estimated patients

Sex

All

Ages

50+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Parkinson Disease (PD) participants must be at least 50 years old and meet clinical diagnostic criteria of idiopathic PD.
Control participants must be at least 50 years old and not have PD, no first-degree family member with PD, and no evidence of PD or dementia on examination.

Exclusion criteria

any history of other neurologic illness (e.g. stroke, seizure, multiple sclerosis)
history of brain surgery or major head trauma
major medical/systemic illness
severe psychiatric illness (e.g. bipolar disorder, schizophrenia)
major drug abuse
history of long term use of anti-dopaminergic medication
chronic treatment with immunomodulatory or anti-inflammatory medications
weight over 300 lbs
contraindication to or inability to tolerate MRI